Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib Extension in IgA Nephropathy
NCT02433236Phase 2Withdrawn
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fostamatinib in IgA nephropathy (IgAN), sponsored by Rigel Pharmaceuticals, Inc.. Planned start Sep 2015; status: withdrawn.
02
Drugs
fostamatinib
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02433236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433236.